Straight answers on peptides,
before everyone else has them.
A short weekly briefing on the U.S. peptide market — what's legal, what's hype, what's next. Written for people who want to understand this before their cousin starts selling it at Thanksgiving.
→ Subscribe · Free · One email per week
No spam. No affiliate links. No supplements to sell you. Unsubscribe in one click.
§ 01 · What this is
The peptide industry is about to get loud. Most of what you'll hear will be wrong.
Regulatory literacy, in plain English
FDA panels, Category 1 vs Category 2, compounding pharmacies, 503A. We translate it so you can tell the difference between what's legal, what's reviewable, and what's just someone selling on Telegram.
Evidence, weighted honestly
Where the human data is strong, we say so. Where it's twelve rats and a hunch, we say that too. We are not your biohacker cousin.
The market, from above
Who's building, who's lobbying, who's about to get steamrolled. The business of peptides is as interesting as the science — and more profitable to understand.
§ 02 · Why now
The three months that will define the next three years.
Feb 27, 2026
The announcement
HHS Secretary signals intent to reclassify 14 of 19 restricted peptides. The internet loses its mind. Nothing legally changes.
Apr 15, 2026 · Present
FDA calls the meeting
Advisory panel scheduled for July 23–24 to review seven peptides. Not a vote on legalization — a discussion about whether to discuss it.
Jul 23–24, 2026
The hearing
Panel recommends, FDA decides later. Rulemaking could take months. This is where the noise-to-signal ratio gets terrible.
Late 2026 · 2027
The rush
Compounding pharmacies, telehealth clinics, supplement brands, and dedicated peptide startups all fight for the same patient. We'll be watching.
§ 03 · What's coming
A preview of the first few issues.
The Opening Brief: what this is and why you should read it Positioning, scope, and the one rule we won't break.
What actually happens on July 23 A realistic read on the FDA advisory meeting — and why the headlines will get it wrong.
BPC-157: the peptide everyone's talking about What the evidence says, what it doesn't, and the story of how one compound became a culture war.
§ Subscribe
One email. One good think. Weekly.
If you hate it, one click gets rid of us.